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Abstract
GADD45 genes are epigenetically inactivated in various types of cancer and tumor cell lines. To date, defects of
the GADD45 gene family have not been implicated in osteosarcoma (OS) oncogenesis, and the role of this path-
way in regulating apoptosis in this tumor is unknown. The therapeutic potential of Gadd45 in OS emerged when
our previous studies showed that GADD45A was reexpressed by treatment with the demethylation drug decita-
bine. In this study, we analyze the OS cell lines MG63 and U2OS and show that on treatment with decitabine,
a significant loss of DNA methylation of GADD45A was associated with elevated expression and induction of
apoptosis. In vivo affects of decitabine treatment in mice showed that untreated control xenografts exhibited
low nuclear staining for Gadd45a protein, whereas the nuclei from xenografts in decitabine-treated mice exhibited
increased amounts of protein and elevated apoptosis. To show the specificity of this gene for decitabine-induced
apoptosis in OS, GADD45A mRNAs were disrupted using short interference RNA, and the ability of the drug to
induce apoptosis was reduced. Understanding the role of demethylation of GADD45A in reexpression of this path-
way and restoration of apoptotic control is important for understanding OS oncogenesis and for more targeted
therapeutic approaches.
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Introduction
Methylation-mediated silencing of genes is one of the most impor-
tant epigenetic mechanisms implicated in the regulation of normal
gene expression. Such changes often affect 5′ regulatory CpG ge-
nomic regions and can be associated with aberrant expression of
certain genes in cancer (reviewed in the study of Esteller [1]). Epige-
netic alterations are considered to contribute in several ways to on-
cogenesis; for example, by activating oncogenes, by silencing tumor
suppressor genes, or by disrupting pathways that contribute to tu-
morigenesis such as those governing apoptosis [2,3].
There is increasing interest in the use of new epigenetic therapies
that might modulate molecular pathways central to tumorigenesis
[4,5]. The most frequently used treatment at present is the DNA
methyltransferase inhibitor, 5-aza-2′-deoxycytidine (decitabine) [6].
This drug is a cytosine analog that inhibits DNA methylation and
can reactivate the expression of transcriptionally silenced genes. Such
repression of gene expression in tumors is thought to occur by spe-
cific CpG methylation of dinucleotide clusters within CpG islands
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that are present in the promoters and span exonic and intronic re-
gions at many loci throughout the human genome [7]. Demethyla-
tion may remove tumor-specific repression within regulatory regions
and permit activation of genes controlling pathways highly pertinent
to oncogenesis, such as apoptosis, proliferation, invasion, and so on.
Previously, we showed that decitabine treatment of the osteo-
sarcoma (OS) cell line U2OS led to the upregulation of >50 genes
possessing CpG islands at their 5′ region [8]. One of the decitabine-
activated genes of importance in OS oncogenesis was GADD45A.
This gene belongs to the stress-responsive GADD45 family that
was reported to be methylated in multiple tumors [9,10]. GADD45A
is relevant to OS tumorigenesis because of its central role in apoptosis
and the P53 pathway [11–13]. Moreover, Gadd45a is a central player
in the maintenance of genomic stability, and loss of protein function
can lead to centrosome amplification, chromosomal instability, and
increased aneuploidy [14,15]. Because generalized loss of genome
stability is characteristic of OS tumors [16–19], the role of this pro-
tein in OS is highly relevant. At the molecular level, the promoter
region of GADD45A has a repression-binding site for c-MYC gene
[20] that is known to be amplified in OS. Also, GADD45A promoter
has a binding locus for P53 in the third intronic region of the gene,
and its functionality is linked to the activation of G1/S cell cycle
arrest in response to ionizing radiation [21]. Significantly, Gadd45a
activation was previously shown to result in the induction of apop-
tosis in several cancer cell lines including COS, PC-3, DU145, and
HeLa cell lines [10,22–24].
Methylation within the 5′ region of GADD45A is likely to be a
major mechanism of repression and inactivation of the protein’s apop-
totic function. There is a region with dense repetitive CG sequence
(CpG island) near the transcription start site (TSS) of GADD45A that
spans 1357 bp and covers the first three exons of the gene [8,25].
Methylation of this CpG island was reported in breast cancer tissues
[25]. A cluster of eight CpG dinucleotides within the first intron of
GADD45A was found to be methylated in the OS cell line U2OS
in vitro and in xenografts [8]. Our previous study demonstrated that
induction of apoptosis in U2OS followed decitabine treatment, but
the precise role of GADD45A CpG island demethylation and the spec-
ificity of Gadd45a expression in the induction of apoptosis were
not defined. The present study was designed to examine the role of
decitabine-dependent GADD45A CpG island demethylation on the
expression of the gene and on subsequent induction of apoptosis in
OS cell lines. These analyses will help determine whether GADD45A
is a potential therapeutic effector and useful biomarker of apoptosis for
future clinical trials in OS that involve genome-wide demethylation.
Materials and Methods
Cell Cultures and Treatment
The human OS cell lines U2OS (ATCC # HTB-96) and MG63
(ATCC # CRL-1427) and cervical adenocarcinoma (HeLa) cell lines
(ATCC # CCL-2) were purchased from American Type Culture
Collection (ATCC, Rockville, MD) and maintained in ATCC rec-
ommended medium. Normal osteoblasts are a primary osteoblasts
from the hipbone of normal male donor that were purchased from
PromoCell, Heidelberg, Germany (catalogue # C-12760) and main-
tained in medium provided by the manufacturer and used at culture
passage 3. Treatment with decitabine was performed as described by
Liang et al. [26]. Briefly, 5 × 105 cells were plated in 56-cm2 culture
plates with 10 ml of growth medium. At 12 hours after plating, they
were treated with freshly prepared decitabine (Sigma Chemical Co.,
St Louis, MO) to a final concentration of 1 μM without changing
the medium. Decitabine was added to the medium only once to
minimize the drug toxicity that is not resulting from drug effects
on DNA methylation [26]. Three days after initiating the treatment,
cells were harvested for RNA and DNA extraction or Hoechst 33342
staining. The use of a single-dose decitabine to significantly reactivate
methylation-silenced genes was reported in bladder cancer cells [26].
Other treatment schedules analyzing demethylation in lung, head,
and neck tumors have involved fresh decitabine when culture media
is replaced [27].
U2OS Xenografts and Treatment
Decitabine treatment of U2OS xenografts was previously de-
scribed [8]. Immune-deficient mice were bred and maintained, and
xenograft experiments were performed by the Animal Resource Cen-
tre at the British Colombia Cancer agency, Vancouver, Canada.
Xenografts were established under the renal capsule, and host mice
were treated intraperitoneally with three doses (2-day intervals) of
decitabine (2.5 mg/kg body weight) dissolved in saline (0.9% w/v
NaCl) or saline alone (control). Mice were sacrificed 5 days after
the last treatment, and the xenograft tissues were snap-frozen or were
prepared in paraffin and sectioned using standard procedures [28].
Knockdown By Gadd45a-siRNA and Transient Transfection
of GADD45A
Silencer predesigned short interference RNA (siRNA) for human
GADD45A (siRNA ID: 146174) and control nontargeting RNA
(ctRNA) were obtained from Ambion, Foster City, CA. Transfection
of OS cells with siRNA was performed using siPORT Amine trans-
fection agent (Ambion) in six-well plates according to manufacturer’s
protocol at the concentration of 60 nM. Decitabine (1 μM) treat-
ments were done 12 hours after plating. RNA and protein was
extracted at specified time points. For the transient transfection ex-
periments, 2 μg of pCMV(GADD45A) or the empty pCMV vectors
(TrueClone; OriGene, Rockville, MD) with 10 μl of Lipofectamine
2000 (Invitrogen, Burlington, Ontario, Canada) were used in the
transfection experiments in six-well plates according to the manufac-
turer’s protocol. Three days later, protein was extracted for Western
blot analysis.
Quantitative Bisulfite Pyrosequencing (Pyro-Q-CpG)
Pyro-Q-CpG primers and protocol were previously described [8].
Genomic DNA from the control and decitabine treatment was
bisulfite-treated using the Zymo DNA Methylation Kit (Zymo Re-
search, Orange, CA). Bisulfite-treated DNA was PCR-amplified and
sequenced according to standard protocol (Biotage, Kungsgatan,
Sweden). The criteria for a CpG island was based on those outlined
by Takai and Jones [29], also see [8], where the GC ≥ 55%, Obs/
Exp ≥ 0.65, and length >300 bp which was reported to exclude most
Alu-repetitive elements. We identified the genes that harbored CpG
island within a 2000-bp window upstream or downstream from the
TSS–based Human Genome Browser database (http://genome.ucsc.
edu/). To be certain that there were no CpG island closer to the
TSS and gene promoter regions, we submitted the sequences of interest
(including a 2000-bp window upstream and downstream from TSS) to
the CpG search engine available in Reference [29].
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Reverse Transcription and Quantitative Real-Time PCR
Total RNA from U2OS, MG63, and NHOst cells was extracted
using TRIzol method (Invitrogen, Osaka, Japan). Total RNA was
reverse-transcribed with the GeneAmp kit (Applied Biosystems;
ABI, Foster City, CA). About 20 ng of the resulting cDNA was
used for TaqMan real-time PCR GADD45A expression assay
(Hs00169255_m1; ABI). All reactions were done in triplicate in
a 384-well plate using the 7900 Sequence Detector System (ABI).
Data analysis was performed by applying the ΔΔCt method relative
to nontreated osteoblast with β-actin as reference gene.
Immunohistochemistry and Image Analysis
Xenograft tissue and pelleted paraffin-embedded formalin-fixed
HeLa cell sections were deparaffinized and rehydrated before incuba-
tion at room temperature in 3% H2O2 in PBS for 10 minutes. Slides
were washed in PBS three times for 3 minutes each. Antigen retrieval
Figure 1. GADD45A CpG methylation in osteosarcoma cells. (A) Schematic of GADD45A genomic locus. 5′ CpG island spanning the first
three exonic regions of GADD45A is shown. An amplicon of ∼250 bp was amplified, and a cluster of eight CG dinucleotides in a ∼50-bp
region within the amplicon was analyzed by Pyro-Q-CpG. The schematic was taken from the latest build of the Human Genome Browser
database: http://genome.ucsc.edu/cgi-bin/hgGateway. The CpG island conforms to the criteria detailed in the Materials and Methods
section. (B) Percentage of methylated alleles on the eight CpG positions in U2OS, MG63, and osteoblasts as detected by Pyro-Q-CpG.
Each data column is the mean percentage of methylated alleles for each CpG position in three experiments. The y-axis indicates the
percentage of methylation, and the samples are indicated on the x-axis. The location of CpG positions relative to the gene start site and
to each other was shown previously [8]. Methylation percentage in U2OS, MG63, and normal osteoblasts (NHOst) with (+) and without
(−) 1 μM decitabine is shown for eight CpG positions in GADD45A promoter.
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was performed at 95°C for 30 minutes in 10-mM sodium citrate
(pH 6.0). After cooling in a running water bath for 5 minutes and
PBS wash, the slides were blocked in 3% skim milk for 30 minutes.
Blocking solution was rinsed briefly, and slides were incubated at 4°C
overnight with 500× dilution of primary anti–human Gadd45a-Ab
(Abnova, Taipei City, Taiwan). After the PBS wash, subsequent
steps were performed using DakoCytomation Kit (Dako, Glostrup,
Denmark) as per manufacturer’s protocol. Hematoxylin was used for
counterstaining, and slides were mounted and scanned by ScanScope
CS (Aperio Technologies, Vista, CA) as previously described [8].
Positive controls were generated by exposing HeLa cells to ultraviolet
(UV) radiation at 10 μJ/cm2 [24]. These cells were then mounted on
slides and processed identically to the experimental xenografts. The
extent of positivity was determined by comparing the xenograft tissue
sections to the control slides derived from HeLa cells. To confirm
that each section retained immunoreactivity, a positive finding for
the Ki67 antibody stain indicated that adjacent xenograft sections
were positive and informative.
Western Blot Analysis
Cells were lysed in culture plates on ice using radioimmunopre-
cipitation buffer. Lysates were sonicated briefly on ice and centrifuged
at high speed for 15 minutes at 4°C. Total protein was quantitated
using Bradford reagent (Bio-Rad, Hercules, CA). About 50 μg of
total protein/well was separated on acrylamide gel and was transferred
to polyvinyl derivative membranes at 25 V at 4°C overnight. Mem-
branes were blocked with 5% BSA for 8 hours at 4°C, followed by
a 16-hour primary antibody incubation [1:12,000 mouse monoclonal
anti–human Gadd45a-Ab (Abnova) or 1:24,000 rabbit polyclonal anti–
human β-actin–Ab (Abcam, Cambridge, MA)]. The blots were washed
with TBS–Tween 20 five times for 10 minutes each and a final wash
with TBS. The blots were incubated with perioxidase-labeled secondary
antibody (ECL-Plus kit; Amersham, Buckinghamshire, UK) as per
manufacturer’s instructions at a dilution of 1:20,000 and were scanned
on the Typhoon 9410 scanner (Amersham) at normal sensitivity,
600 laser, and 200-μm resolution. Quantitation was performed using
ImageJ software on blots from three replicates, and significance was
estimated using t test at P < .05 and β-actin levels served as a control.
Hoechst 33342 Staining for Apoptotic Nuclei
The cells were trypsinized and resuspended in 1 ml of PBS. Stain-
ing was performed in 5 ml of 4% formalin solution with Hoechst
33342 dye (0.01-μg/μl final concentration). Aliquots of the samples
were bar-coded before spreading the cells on glass slides. Hoechst-
stained cells were blindly analyzed using a fluorescence microscope.
One hundred cells were scored per slide, and the percentage of
stained (apoptotic nuclei) out of total was recorded. Triplicate experi-
ments were analyzed using Student’s t test at P < .05.
Statistical Test
Student’s t test was applied to analyze the differences between
treatment groups.
Results
CpG Methylation of GADD45A in OS Cells
GADD45A repression of expression in U2OS in vitro and in xeno-
grafts was shown previously by our group to be associated with 5′
Figure 2. Repression of GADD45A expression. (A) Induction of GADD45A mRNA expression in U2OS and MG63 after decitabine treat-
ment. Total RNA was extracted on day 3 after decitabine treatment was initiated. cDNA was then made as detailed in the Materials and
Methods section. TaqMan assays were used to determine relative expression using the cDNA from untreated osteoblast as baseline
and β-actin for a reference gene by applying the ΔΔCt method. Each column is the mean of three replicates, and error bars indicate
standard deviation from the mean. In these analyses, GADD45AmRNA levels are shown as fold regulation compared with the untreated
normal osteoblasts. NHOst indicates normal human osteoblasts; nt, no treatment; tr, treated by decitabine. (B and C) Decitabine-related
Gadd45a protein induction in U2OS and MG63 cells. Protein preparations from cells with or without treatment were done 3 days after
initiating the treatment. For each sample, a total of 50 μg of protein was examined by Western blot analysis, and β-actin was used as a
loading control. The shown blot in (B) is representative from three experiments, and the mean ± SD from quantification of three replicas
after normalization to β-actin is shown on the graph in (C). Asterisks denote statistical significance compared with the no-treatment cells
and nontreated osteoblasts.
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CpG island hypermethylation of a cluster of eight CpG dinucleotides,
within the first intronic region of the gene 620 bp downstream of the
TSS (Figure 1A) [8]. In this study, quantitative bisulfite pyro-
sequencing (Pyro-Q-CpG) showed that ∼80% of the sequenced alleles
from the eight CpG dinucleotides in GADD45A of MG63 were
methylated (Figure 1B). Exposure of MG63 to 1-μM decitabine sig-
nificantly decreased methylation (P < .001) to ∼55% of sequenced
alleles at the eight CpG dinucleotides (Figure 1B). Moreover, meth-
ylation repression of GADD45A in MG63 was implicated because
mRNA expression was found to be reduced at levels slightly lower
than those of normal low-passage osteoblasts (Figure 2A). Importantly,
loss of DNA methylation was associated with a 3.5-fold increase in
GADD45A mRNA expression relative to normal osteoblasts and a
six-fold increase relative to untreated MG63 cells as detected by quan-
titative real-time PCR (Figure 2A). Similar observations were found in
U2OS cells, which confirmed the previous results published by our
group [8]. Interestingly, very low methylation (range, 0.1–2.9% meth-
ylation of sequenced alleles) was observed at all eight CpG dinucleo-
tides in both treated and untreated osteoblasts (Figure 1B). Moreover,
GADD45A mRNA expression in osteoblasts was not induced after
decitabine treatment (Figure 2A).
To confirm that induction of mRNA expression led to a concom-
itant increase in Gadd45a protein levels, Western blot analyses were
performed on cell extracts from both decitabine-treated and un-
treated U2OS and MG63 cells (Figure 2, B and C). In both cell lines,
the levels of Gadd45a protein induction after decitabine treatment
were similar to that observed in the mRNA levels.
Decitabine Induces Significant Levels of Gadd45a Protein
in OS Cells
To investigate the level of Gadd45a protein induction in U2OS
xenografts, six xenografts (three from no treatment and three from
decitabine-treated) were analyzed by immunohistochemistry using
a human Gadd45a antibody. Sections from cell pellets prepared from
the Gadd45a-activated UV-treated HeLa cells were used as positive
controls. The staining of xenograft nuclei was quantitated using the
intensity of staining and the proportion of positive tumor nuclei. As
shown in Figure 3, A and B, xenograft sections from the untreated
Figure 3. Induction of Gadd45a protein in OS xenografts by decitabine treatment. (A) Induction of Gadd45a protein levels in U2OS
xenografts. Analysis of the relative levels of nuclear Gadd45a protein within xenografts derived from representative control untreated
mice (upper panel) or decitabine-treated mice (lower panel) using immunohistochemical staining with human Gadd45a-Ab. A ×20 en-
largement of representative U2OS histology is shown inside the boxed image. To the right (lower image) in (A) is the darkly stained HeLa
cells corresponding to the induction of Gadd45a after UV exposure (UV+) which was used as positive control. (B) Quantification of
Gadd45a-antibody staining. The staining intensity from control (light columns) and decitabine-treated (dark columns) was quantitated
using Aperio scanning image analysis of sections. Gadd45a-Ab intensity was calculated based on the percentage of positivity (total
positivity/total negativity per snapshot) relative to the positivity index in the positive control (UV-irradiated HeLa cells) after normalization
to negative controls (no Gadd45a-Ab). Determination of the difference between the control and treated xenografts was done by applying
Student’s t test, and P < .05 was considered significant. The columns are the means ± SDs from 5 to 10 (∼0.3 mm2) images after
normalization to positive control. The asterisk denotes statistical significance compared with the no-treatment xenografts.
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control mice exhibited low nuclear staining for Gadd45a, whereas
the staining was stronger and more frequent in nuclei from xeno-
grafts in decitabine-treated mice (P < .05). Induction of Gadd45a
was also found to be associated with increased apoptosis as shown
in a previous analysis on the same U2OS xenografts [8]. In addi-
tion, caspase-9 activation was assessed by immunohistochemistry in
U2OS xenografts using an antibody specific for cleaved (activated)
caspase-9. In this analysis, there was no significant induction of
cleaved caspase-9 (P > .05) as a result of decitabine treatment when
compared to no-treatment xenografts.
Gadd45a-Specific Induction of Apoptosis
Decitabine treatment at 1 μM significantly induced apoptosis
in vitro (P < .05) in both cell lines in comparison to no-treatment
cells (Figure 4A). Similarly, transient transfection of Gadd45a over-
expression vector significantly induced apoptosis (P < .05) in un-
treated U2OS and MG63 in comparison to transfection with
an empty vector (Figure 4A). In both experiments, Western blot
analysis demonstrated activation of the Gadd45a protein (Figure 4,
B and C ). To investigate the specificity of Gadd45a induction on
decitabine-induced apoptosis, GADD45A mRNAs were disrupted
using specific siRNA in U2OS and MG63 cells. The effect of
1-μM decitabine treatment on GADD45A mRNA and protein levels
3 days after treatment was analyzed alone or in combination with
60 nM Gadd45a-siRNAs. Transfection of Gadd45a-siRNA against
a decitabine-treated background reduced GADD45A mRNA levels
in both cell lines by >70% knockdown efficiency (Figure 5A). This
knockdown efficiency was consistently observed in the protein level
in U2OS and MG63 cells as analyzed by Western blot analysis (Fig-
ure 5, B and C ). Decitabine treatment resulted in a five-fold induc-
Figure 4. Apoptosis induction by pCMV-GADD45A in U2OS and MG63. (A) Percentage of apoptotic nuclei as detected by Hoechst stain
in U2OS and MG63. Columns are mean of three replicas, and error bars are standard deviation from the mean. (B) Induction of Gadd45a
protein by decitabine treatment or by Gadd45a transient transfection. Western blot analysis was used to detect protein levels after
treatment with 1-μM decitabine or 2 μg of pCMV(GADD45A) transient transfection vectors (TrueClone). About 10 μl of Lipofectamine
2000 (Invitrogen, Burlington, Ontario, Canada) was used in the transient transfection experiments. (C) The mean ± SD from quantifi-
cation of three replicas after normalization to β-actin. nt indicates no treatment; pCMV(−), empty vector; pCMV(GADD45A), human
GADD45A cDNA cloned in pCMV vector. The asterisk denotes statistical significance compared with the no-treatment or empty vector.
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tion of GADD45A mRNA in U2OS, and six-fold in MG63 cells.
Similar levels of induction were seen in the presence of 60 nM of
scrambled ctRNA in decitabine-treated cells.
To investigate the effect of knocking down Gadd45a protein on
apoptosis levels, nuclei from U2OS and MG63 were stained with
Hoechst 33342 dye at day 3 after treatment in the decitabine-alone
and combination experiments (Figure 6A). Fluorescent microscopy
demonstrated that the fractions of fragmented nuclei caused by
1-μM decitabine treatment were 14% in U2OS and 15% in MG63,
whereas the no-treatment cells or the ctRNA (60 nM) cells (in the
presence of a transfection agent) had a fragmented nuclei (apoptotic
nuclei) percentage of less than 4% in both cell lines (Figure 6B). Deci-
tabine also induced apoptosis to similar levels in U2OS and MG63
when used in combination with same amounts of ctRNA and transfec-
tion agent. Interestingly, when Gadd45a-siRNA (60 nM) was used in
combination with decitabine, apoptotic nuclei were reduced from 14%
to 6% (P < .05) in U2OS and from 15% to 8% in MG63 (P < .05)
(Figure 6, A and B), indicating that decitabine’s ability to induce apop-
tosis was reduced specifically by Gadd45a-siRNA.
Discussion
Osteosarcoma is a particularly aggressive cancer in which current
treatment modalities result in a 5-year event-free survival in 60% to
70% of patients [30,31]. The chemotherapeutic drugs most com-
monly used in the treatment of OS include doxorubicin, high-dose
methotrexate, cis-platinum, and ifosfamide either alone or with
Figure 5. Reduction of GADD45A expression by GADD45A-siRNAs in decitabine-treated U2OS and MG63 cells. (A) Effects of GADD45A-
siRNA on mRNA levels in U2OS and MG63. Total RNA was extracted on day 3 after the decitabine treatment was initiated. Preparation of
cDNA and determination of mRNA relative expression is similar to that outlined in Figure 1C and detailed in the Materials and Methods
section. Each column is the mean of three biologic replicas, and error bars indicate standard deviation from the mean. Data are ex-
pressed as fold change relative to no treatment.Mock indicates transfection agent + medium (no siRNA or ctRNA). (B) Gadd45a protein
levels at day 3 after decitabine treatment. About 50 μg of protein was examined by Western blot analysis for the activation of Gadd45a
protein, and β-actin was used as a loading control. (C) Quantification of Gadd45a protein levels. The level of Gadd45a in the decitabine-
treated and scrambled control RNA-transfected (ctRNA) was set as 100%. The columns are the means ± SDs of three replicas after
normalization to β-actin.
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etoposide (reviewed in the study of Uchida et al. [32]). Unfortunately,
there is a poor response to chemotherapy in a significant subgroup of
OS patients, and some patients have a high drug toxicity profiles [33].
Attempts at changing chemotherapy regimens for poor responders
have generally failed to improve outcome [34].
In recent years, novel therapeutic approaches involving genome-
wide epigenetic modification have been introduced (reviewed in
the study of Issa [6]). Decitabine is one of the most popular in this
class of new drugs, and it has been approved by the US Food and
Drug Administration [35]. The results of early clinical trials using
this drug are promising, but there is little detail available concerning
the molecular pathways leading to tumor response (reviewed in the
study of Kihslinger and Godley [36]). The mechanisms of response
to decitabine may vary in different patients, but they are thought
to include induction of senescence, differentiation, and apoptosis (re-
viewed in the study of Issa [6]).
Previously, we showed that decitabine treatment of the OS cell line
U2OS led to the upregulation of >50 genes possessing CpG islands
at their 5′ region [8]. GADD45A was one of the decitabine-activated
genes that were known to be involved in apoptosis, and importantly,
the function of the protein is relevant to OS oncogenesis. Interest-
ingly, the GADD45 stress-response family has been shown to be
inactivated by methylation in several types of tumors [9] (reviewed
in the study of Zerbini and Libermann [10]). The protein has been
implicated in regulating genome stability (reviewed in the study of
Hollander and Fornace [15]), DNA damage response [11], DNA re-
pair [37,38], apoptosis [24], and most recently, when overexpressed,
DNA demethylation [39]. Despite the impact of GADD45A gene on
all these processes, and its frequent methylation in some tumors,
there is limited information regarding the role of GADD45A in
the response to epigenetic modifications, in general, and to demethy-
lation treatment, in particular.
In this study, we found that extensive methylation of the 5′ CpG
region of GADD45A was present in the MG63 and U2OS cell lines,
and this epigenetic change was associated with the reduced expression
of GADD45A in OS. Furthermore, it was found that exposure of both
OS cell lines to decitabine significantly decreased the methylated alleles
to ∼55% in this region of the gene. The relationship between loss of
DNA methylation in this region, and elevated gene expression was
demonstrated by a six-fold increase in both GADD45A mRNA and
protein levels. The role of Gadd45a on cell cycle arrest is well estab-
lished. The protein has been shown to play a role in G2-M checkpoint
in response to DNA damage. Gadd45a activates p53-dependent G2-M
arrest, providing a link between p53-dependent cell cycle checkpoint
and DNA repair. In this regard, it is noteworthy that p53 inactivation
is one of the most common aberrations observed in human OS (re-
viewed in Kansara and Thomas [40]).
The role of Gadd45a in apoptosis is not as well understood as is its
role in cell cycle arrest. GADD45A overexpression in normal human
fibroblasts and human cancer cells causes G2-M arrest [25,41,42].
Gadd45a-dependent induction of apoptosis has been observed fre-
quently in cancer cell lines [10,24], but its role in apoptosis induc-
tion in normal cells has been controversial. Gadd45a has been shown
to induce cell cycle arrest in normal fibroblasts but fail to induce
apoptosis [41]. Others, however, have shown Gadd45a-dependent
induction of apoptosis in normal epithelial cells [43]. In the present
study, we show that Gadd45a reexpression correlates with a sig-
nificant increase in apoptosis in OS cells. In vivo effects of decitabine
treatment were studied by establishing xenografts and showing that
tumor sections of xenografts from untreated control mice exhib-
ited low nuclear staining for Gadd45a protein, whereas the nuclei
from xenografts in decitabine-treated mice exhibited much higher
levels of Gadd45a protein. As with the in vitro studies, an increase
in Gadd45a protein levels was associated with a significant increase
in apoptosis.
To show the specificity for Gadd45a in decitabine-induced apop-
tosis, GADD45A mRNAs were disrupted using siRNA. This ap-
proach has been used previously in other cell types, and inhibition
of GADD45A led to disruption of functions including its ability to
induce apoptosis [10,44,45]. GADD45A activation in OS was found
to be central to the decitabine-induced apoptosis, and knockdown by
siRNA demonstrated the specificity of this effect. This observation,
however, does not eliminate the possibility of the involvement of the
other apoptotic factors and pathways in the decitabine-induced apop-
tosis in OS cells [8].
Figure 6. Gadd45a-siRNA treatment abolishes decitabine-induced
apoptosis. (A) A representative image of apoptotic nuclei (arrows)
from decitabine-treated MG63 stained with Hoechst 33342 dye.
(B) One hundred nuclei were counted per slide, and three slides
were prepared for each treatment condition. The columns are
the means ± SDs of three biologic replicas. When Gadd45a-siRNA
(60 nM) was added to the medium in combination with decitabine,
apoptotic nuclei were reduced from 14% to 6% (P < .05) in U2OS
and from 15% to 8% in MG63 (P < .05). ctRNA indicates control
nontargeting RNA; G45a, Gadd45a; nt, no treatment; siRNA, short
interference RNA.
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Osteosarcoma is known for having high levels of genomic instabil-
ity with multiple chromosomal breakpoints and increased incidence
in genomic aberrations [17–19,46]. Inhibition of the DNA dam-
age response gene such as GADD45A by DNA hypermethylation
could be one explanation on how OS cells escape apoptosis and un-
dergo survival, despite the numerous DNA breakpoints required to
generate the complex karyotypes that characterize the OS genome.
Interestingly, Gadd45a has recently been shown to actively demeth-
ylate downstream target genes by promoting DNA repair [39] thus
linking both processes. Finally, the findings of a potential role for
GADD45 repression by methylation in OS oncogenesis may encour-
age the development of novel therapeutic strategies that take advantage
of improved understanding of the genomics and epigenomics of
this tumor.
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